» Articles » PMID: 9238656

Interleukin-8 Concentration in Peritoneal Fluid of Patients with Endometriosis and Modulation of Interleukin-8 Expression in Human Mesothelial Cells

Overview
Journal Mol Hum Reprod
Date 1996 Jan 1
PMID 9238656
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-8 (IL-8) is a chemoattractant and activating factor for human neutrophlls and a potent angiogenic agent. The peritoneal fluid of women with endometriosis has been shown to have increased neutrophil chemotactic activity. We postulate that IL-8 may be an important modulator in the pathogenesis of endometriosis and adhesion formation. We first investigated IL-8 concentrations in the peritoneal fluid of women with or without endometriosis, then assessed peritoneal mesothelial cells as a potential source of peritoneal fluid IL-8. Northern blot analysis and enzyme-linked immunosorbent assay (ELISA) were used to investigate IL-8 mRNA and protein modulation. The mean concentration of IL-8 in samples obtained from control patients (n = 28) was 4.8 +/- 0.5 pg/ml; from patients with minimal-mild endometriosis (n = 24) was 27.5 +/- 2.6 pg/ml; and from patients with moderate-severe endometriosis (n = 21) was 530.2 +/- 65.1 pg/ml. Confluent mesothelial cells were incubated with human recombinant IL-1 alpha (0.01-100 IU/ml) or tumour necrosis factor (TNF)-alpha (0.01 to 100 ng/ml) for 2-24 h. IL-8 mRNA was detectable in non-treated cells, however both IL-1 alpha and TNF-alpha induced higher amounts of IL-8 mRNA in a dose- and time-dependent manner. Non-treated mesothelial cells in culture also produced and secreted IL-8 protein quantified by ELISA, but again higher concentrations were induced by IL-1 alpha and TNF-alpha treatment. In conclusion, we found that IL-8 concentrations were elevated in peritoneal fluids from women with endometriosis. Cultured mesothelial cells expressed cytokine-inducible IL-8 mRNA and secreted IL-8 protein. The regulated expression of this angiogenic factor may play a role in pathogenesis of endometriosis.

Citing Articles

Review of the Potential Therapeutic Effects and Molecular Mechanisms of Resveratrol on Endometriosis.

Jiang T, Chen Y, Gu X, Miao M, Hu D, Zhou H Int J Womens Health. 2023; 15:741-763.

PMID: 37200624 PMC: 10187648. DOI: 10.2147/IJWH.S404660.


Bioinformatical analysis of the key differentially expressed genes and associations with immune cell infiltration in development of endometriosis.

Chen S, Chai X, Wu X BMC Genom Data. 2022; 23(1):20.

PMID: 35303800 PMC: 8932180. DOI: 10.1186/s12863-022-01036-y.


PPARγ Agonists: Emergent Therapy in Endometriosis.

Vallee A, Vallee J, Le Blanche A, Lecarpentier Y Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34204039 PMC: 8229142. DOI: 10.3390/ph14060543.


Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.

AlAshqar A, Reschke L, Kirschen G, Borahay M Biol Reprod. 2021; 105(1):7-31.

PMID: 33739368 PMC: 8256101. DOI: 10.1093/biolre/ioab054.


Selection of New Probiotics for Endometrial Health.

Chenoll E, Moreno I, Sanchez M, Garcia-Grau I, Silva A, Gonzalez-Monfort M Front Cell Infect Microbiol. 2019; 9:114.

PMID: 31058101 PMC: 6481279. DOI: 10.3389/fcimb.2019.00114.